Turbine, a Budapest, Hungary-based simulation-based drug discovery company, raised €3m in funding.
The round was led by Delin Ventures, with participation from follow-on angel investors such as Esther Dyson, Vishal Gulati and Atlantic Labs, as well as o2h Ventures. Alan Barge, former VP & Head of Oncology Therapy Area at AstraZeneca and Partner at Delin Ventures, joined the Board of Directors of Turbine.
The company intends to use the funds to expand the rational, simulation-based drug discovery workflow into every phase of drug discovery from research to lifecycle management.
Led by Szabolcs Nagy, CEO, Turbine built the Simulated Cell platform, which is comprised of a dynamic computational model of the human cell and the underlying simulation technology to find the smartest route to novel targets, biomarkers, and combination therapies.
Its in silico experiments can test an almost infinite number of interventions on a Simulated Cell that reflects the molecular diversity of cancer cells accurately.